<DOC>
	<DOCNO>NCT00078923</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent delay development early cancer . Soy isoflavones may effective delaying development early prostate cancer . PURPOSE : This randomized phase II trial study different regimen soy isoflavones compare well work treat patient undergo radical prostatectomy stage I stage II prostate cancer ( adenocarcinoma ) .</brief_summary>
	<brief_title>Soy Isoflavones Treating Patients Who Are Undergoing Radical Prostatectomy Stage I Stage II Adenocarcinoma Prostate</brief_title>
	<detailed_description>OBJECTIVES : - Compare blood/prostate biomarkers oxidative stress prostate cancer risk patient stage I II adenocarcinoma prostate treat 3 different dose level soy isoflavones radical prostatectomy . - Compare prostatic tissue biomarkers proliferation apoptosis patient treat regimen . - Determine potential response , term tumor prostatic intraepithelial neoplasia grade volume , extraprostatic extension , serum prostate-specific antigen level , patient treat soy isoflavones treat placebo . - Determine safety soy isoflavone supplementation patient . OUTLINE : This randomize , double-blind , placebo-controlled , parallel-group study . Patients stratify accord tumor stage ( T1c v T2 ) . Patients randomize 1 4 treatment arm . - Arm I ( control group ) : Patients receive oral placebo daily . - Arm II : Patients receive oral soy isoflavones oral placebo daily . - Arm III : Patients receive high dose oral soy isoflavones oral placebo daily . - Arm IV : Patients receive high dose ( high arm III ) oral soy isoflavones daily . In arm , treatment continue 2-6 week ( depend time study entry plan surgery ) absence unacceptable toxicity . All patient undergo radical prostatectomy . Patients follow 1 week . PROJECTED ACCRUAL : A total 100 patient ( 25 per treatment arm ) accrue study within 12.5 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Stage T1c T2 Disease confine prostate gland Planning undergo radical prostatectomy within next 34 week PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic ALT AST less 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Renal Not specify Other Fertile patient must use effective barrier contraception Medically clear surgery No concurrent thyroid disease PRIOR CONCURRENT THERAPY : Biologic therapy No prior biological therapy prostate cancer No concurrent biological agent Chemotherapy No prior chemotherapy prostate cancer No concurrent chemotherapy Endocrine therapy No prior hormonal therapy prostate cancer No concurrent thyroid hormone replacement medication No concurrent hormonal therapy Radiotherapy Not specify Surgery See Disease Characteristics Other At least 3 month since prior highdose nutritional supplement No concurrent regular use ( weekly ) soy product great 50 g soy protein 50 mg soy isoflavone No concurrent highdose nutritional supplement Standarddose single multivitamin tablet ( e.g. , Centrumâ„¢ ) allow No concurrent herbs No concurrent soy foods No concurrent isoflavone supplement No concurrent antineoplastic agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>